1. Epidemiology and Global Health
  2. Microbiology and Infectious Disease
Download icon

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

  1. Nick K Jones
  2. Lucy Rivett
  3. Shaun Seaman
  4. Richard J Samworth
  5. Ben Warne
  6. Chris Workman
  7. Mark Ferris
  8. Jo Wright
  9. Natalie Quinnell
  10. Ashley Shaw
  11. Cambridge COVID-19 Collaboration
  12. Ian G Goodfellow
  13. Paul J Lehner
  14. Rob Howes
  15. Giles Wright
  16. Nicholas J Matheson
  17. Michael P Weekes  Is a corresponding author
  1. Cambridge University NHS Hospitals Foundation Trust, United Kingdom
  2. Clinical Microbiology & Public Health Laboratory, Public Health England, United Kingdom
  3. Medical Research Council Biostatistics Unit, University of Cambridge, United Kingdom
  4. Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, United Kingdom
  5. Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, United Kingdom
  6. Department of Medicine, University of Cambridge, United Kingdom
  7. Occupational Health and Wellbeing, Cambridge Biomedical Campus, United Kingdom
  8. Division of Virology, Department of Pathology, University of Cambridge, United Kingdom
  9. Cambridge COVID-19 Testing Centre and AstraZeneca, Anne McLaren Building, United Kingdom
  10. NHS Blood and Transplant, United Kingdom
  11. Cambridge Institute for Medical Research, University of Cambridge, United Kingdom
Research Advance
Cite this article as: eLife 2021;10:e68808 doi: 10.7554/eLife.68808
1 figure, 1 table and 1 additional file


Proportion of positive screening tests for SARS-CoV-2 amongst HCWs from the CUHNHFT asymptomatic screening programme (grey bars; week 1, 18–24 January 2021; week 2, 25–31 January 2021) and Ct values of positive tests (Ct < 36; blue dots; both weeks).

RT-PCR targeting the SARS-CoV-2 ORF1ab genes was conducted at the Cambridge COVID-19 Testing Centre (part of the UK Lighthouse Labs Network). For proportions of positive screening tests, p-values for pair-wise comparisons of unvaccinated HCWs with HCWs <12 days or ≥12 days post-vaccination are shown (Fisher’s exact test; both weeks). For Ct values, medians ± interquartile ranges are shown.

Figure 1—source data 1

Proportions of positive asymptomatic SARS-CoV-2 screens and distributions of Ct values.



Table 1
Weekly numbers and proportions of positive SARS-CoV-2 test results spanning 6 weeks around the main study period (indicated in grey).
Unvaccinated<12 Days since vaccination≥12 Days since vaccination
Week startTotal testsPositive tests%Total testsPositive tests%Total testsPositive tests%
28 December 20202097160.8%800.0%600.0%
4 January 20214762430.9%9300.0%2200.0%
11 January 20213273270.8%97860.6%3000.0%
18 January 20212183170.8%171680.5%48310.2%
25 January 2021106990.8%181950.3%150630.2%
1 February 202169910.1%75810.1%282510.0%

Additional files

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)